Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil augmentation in late-life depression (MTLD III)
NCT00177671Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2003
- Primary completion
- Sep 2009
- Countries
- 1
- Sponsor
- University of Pittsburgh
- Modality
- Small Molecules
- Drugs
- donepezil
- Conditions
- major depressive disorder (MDD)
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Donepezil Augmentation with Placebo Augmentation (2 arms). Primary endpoints: Global Cognitive Performance at 2 years, Cognitive Instrumental Activities of Daily Living at 2 years and 1 more. Started Dec 2003; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Donepezil Augmentation
Antidepressant + Donepezil
Placebo Augmentation
Antidepressant + Placebo
03
Endpoints
Primary
Global Cognitive Performance
Cognitive Instrumental Activities of Daily Living
Number of Participants With Recurrence of Major Depression
Beyond the preview
Go deeper on NCT00177671.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177671.